Belgian biotech company Rewind Therapeutics said on Thursday that it plans to discover and develop first-in-class inhibitors of a key GPCR (G protein-coupled receptor) target that has an influential role in myelin-related neurological diseases under a EUR2.9m grant from Flanders Innovation and Entrepreneurship (VLAIO).
Rewind's collaboration partners include the Stem Cell Institute at KU Leuven (KUL) and imec, a research based nanoelectronics and digital technologies company.
Under the partnership, KUL will develop cellular screening assays based on human stem cells to assess the potential of small molecule candidates to block the target GPCR and induce nerve remyelination and imec will devise a novel chip-based engineering approach to measure nerve myelination.
According to Rewind, the collaboration partners will provide state-of-the-art and complementary expertise necessary to establish a disruptive innovation platform for studying the biology of nerve myelination and neuronal function and provide unique advantages in discovering and advancing new potent and selective drugs for nerve and brain repair.
Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial